BostonGene to Present AI Platform at Japanese Oncology Meeting
BostonGene, a pioneering provider of AI-driven molecular and immune profiling solutions, is set to participate in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025), which will be held from March 6 to 8, 2025, in Kobe, Japan. The JSMO conference is a prestigious gathering that brings together global experts in oncology to discuss the latest advancements in precision medicine and foster collaboration across the field. BostonGene’s participation underscores its commitment to advancing cancer treatment through cutting-edge technologies in multiomics and artificial intelligence.
The company is poised to showcase its innovative AI-powered multiomics platform that plays a crucial role in transforming the understanding of cancer biology and improving treatment selection. By integrating various data types—including genomics, transcriptomics, and immune profiling—BostonGene’s platform provides a comprehensive view of the molecular and immune landscape of tumors. This integration not only enhances the understanding of cancer but also aids in identifying new biomarkers that are essential for making informed treatment decisions.
During the conference, Nathan Fowler, MD, Chief Medical Officer at BostonGene, will deliver a keynote presentation titled “Cutting Edge of Genomic Medicine and Novel Therapy in Hematologic Malignancies.” In his address, Dr. Fowler will delve into the role of BostonGene’s multiomics platform in advancing the treatment of hematologic malignancies, such as leukemia and lymphoma. He will highlight how the company, in collaboration with leading clinical partners, leverages these multiomics techniques to identify biomarker predictors that are critical for treatment success. Furthermore, Dr. Fowler will discuss how these insights are driving the next evolution in drug development, particularly for diseases that have historically been difficult to treat.
Key Presentations at JSMO2025
BostonGene will also present a series of oral and poster presentations during the conference, which will further illustrate how its advanced technologies are shaping the future of cancer treatment. These presentations include:
Oral Presentation: Multiomic Clustering of Cutaneous Melanoma Patients to Reveal Survival Trends Based on Tumor Immune Evasion Features
This presentation will showcase BostonGene’s novel approach of combining genomic and transcriptomic data to analyze tumor immune microenvironment patterns in patients with cutaneous melanoma. By focusing on immune evasion features, the research aims to reveal survival trends and provide insights into how tumors evade immune detection. Understanding these mechanisms is critical for developing more effective immunotherapies.
Oral Presentation: Unraveling Sarcomatoid Features in Clear Cell Renal Cell Carcinoma with RNA-seq
This presentation will highlight the value of predictive modeling in the development of targeted therapies for clear cell renal carcinoma. By using RNA sequencing, the research aims to identify key molecular characteristics of the sarcomatoid features in this type of cancer. BostonGene’s Tumor Portrait™ test will be highlighted as an effective tool for identifying unique and targetable clinical characteristics, which can lead to more personalized and precise treatments.
Poster Presentation: Effective Immune-Based Treatment of Extraskeletal Myxoid Chondrosarcoma Guided by Next-Generation Gene Profiling
In this poster presentation, BostonGene will showcase cases of advanced extraskeletal myxoid chondrosarcoma, a rare cancer with limited treatment options. The study will demonstrate how BostonGene’s comprehensive genomic profiling platform has been instrumental in guiding the selection of targeted immune-based therapies for these patients, offering hope for those with challenging cancers.
Poster Presentation: Leveraging Mappability and Analysis of Allele Frequencies to Mitigate False Positive Germline Variant Calling
This study presents BostonGene’s advanced bioinformatic techniques designed to improve the accuracy of germline variant detection in next-generation sequencing. The research focuses on leveraging mappability and allele frequency analysis to mitigate the risk of false positive results in germline variant calling. This approach enhances the reliability of genetic testing, which is essential for accurate diagnosis and personalized treatment plans.
BostonGene to Present AI Platform at Japanese Oncology Meeting
Oral Presentation: Evaluating the Clinical Utility of RNA- and DNA-Based Comprehensive Genomic Profiling in Patients with Advanced Cancers
BostonGene will present the findings from a large prospective research study that evaluates the diagnostic and clinical utility of RNA- and DNA-based comprehensive genomic profiling in patients with advanced cancers. This study aims to demonstrate how comprehensive genomic profiling can improve clinical decision-making, leading to more personalized treatments that optimize patient outcomes.
Oral Presentation: Machine Learning-Enabled Automation for High-Throughput Data Processing in Flow Cytometry
In this innovative study, BostonGene will introduce its machine learning-based cell classification algorithm, which is designed to automate and accelerate data processing in flow cytometry. This algorithm significantly reduces the turnaround time for analyzing cell populations, enabling researchers and clinicians to make faster and more informed decisions regarding cancer treatment.
The Role of AI in Precision Oncology
BostonGene’s participation in JSMO2025 comes at a time when artificial intelligence is increasingly being recognized for its potential to revolutionize precision oncology. By integrating AI with multiomics, BostonGene’s platform offers a sophisticated and data-driven approach to understanding the complex biological and immunological factors that drive cancer. AI enables the platform to analyze vast amounts of data quickly and accurately, uncovering insights that would be difficult to obtain through traditional methods.
The company’s cutting-edge technologies are not only improving cancer diagnostics but also paving the way for more effective and personalized treatment strategies. As the field of oncology continues to evolve, the ability to integrate multi-modal data and apply AI-driven insights is expected to play an essential role in advancing cancer care worldwide.
Conclusion
BostonGene’s presence at the 22nd Annual Meeting of the Japanese Society of Medical Oncology is a significant milestone in the company’s ongoing mission to drive innovation in cancer treatment through AI and multiomics. The research and findings presented at the conference will highlight the transformative potential of these technologies, offering new hope for patients and providing clinicians with powerful tools to make more informed treatment decisions. With its commitment to advancing precision oncology, BostonGene is poised to make a lasting impact on the future of cancer care.
About BostonGene Corporation
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.
About BostonGene Japan
BostonGene Japan Inc., a Tokyo-based joint venture formed by BostonGene, NEC Corporation and Japan Industrial Partners aims to advance personalized medicine and dramatically improve patient outcomes. The company leverages BostonGene’s AI-powered multiomics platform to accelerate drug development and personalize cancer therapies for each patient.
